Zhi Tong Cai Jing·2025-08-19 00:30Core Viewpoint - Rongchang Biologics (688331.SH) has entered into an agreement with Santen Pharmaceutical Co., Ltd.'s wholly-owned subsidiary, Santen (China) Co., Ltd., granting exclusive rights for the development, production, and commercialization of the RC28-E injection in several Asian markets, while retaining global rights outside these regions [1][2]. Group 1: Agreement Details - Rongchang Biologics will receive a non-refundable and non-offsettable upfront payment of 250 million RMB from Santen China [1]. - The agreement includes potential milestone payments of up to 520 million RMB for development and regulatory achievements, and up to 525 million RMB for sales milestones [1]. - Additionally, Rongchang Biologics will earn a tiered sales royalty based on product sales in the authorized regions, ranging from high single-digit to double-digit percentages [1]. Group 2: Product and Market Impact - RC28-E injection is a dual-target fusion protein drug developed by Rongchang Biologics for treating ocular neovascular diseases [2]. - The collaboration is expected to accelerate market access and patient coverage for RC28-E, significantly shortening the commercialization cycle [2]. - This partnership aims to provide innovative and efficient solutions for the treatment of retinal diseases [2].